Advanced Triple Therapy for COPD & Severe Asthma Management
Respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and severe asthma continue to affect millions of people worldwide. The combination of Vilanterol, Glycopyrronium, and Fluticasone provides comprehensive symptom control by combining three proven medicines in one inhaler. This triple therapy is widely prescribed by respiratory specialists for patients requiring long-term maintenance treatment.
Cordium Pharmaceuticals is a trusted pharmaceutical exporter from India, supplying high-quality respiratory medicines to international distributors, hospitals, pharmacies, government procurement agencies, and healthcare organizations.
Composition
Each inhaler contains:
Vilanterol (Long-Acting Beta2 Agonist ā LABA)
Glycopyrronium (Long-Acting Muscarinic Antagonist ā LAMA)
Fluticasone (Inhaled Corticosteroid ā ICS)
This triple combination helps improve lung function, reduces airway inflammation, and keeps the airways open for easier breathing.
Medical Benefits
Provides long-lasting bronchodilation.
Reduces airway inflammation.
Improves breathing capacity.
Helps decrease COPD exacerbations.
Reduces hospitalization risk.
Improves exercise tolerance.
Enhances quality of life.
Convenient once-daily maintenance therapy.
Supports long-term respiratory disease management.
Indications
This medicine is commonly prescribed for:
Chronic Obstructive Pulmonary Disease (COPD)
Severe persistent asthma (when appropriate and prescribed by a physician)
Patients with frequent respiratory exacerbations requiring triple inhaled therapy
Note: This inhaler is a maintenance treatment and is not intended for the immediate relief of sudden breathing attacks.
Dosage and Administration
Use only as directed by a qualified healthcare professional.
The commonly prescribed regimen is one inhalation once daily, depending on the specific strength and product approved in the destination country.
Use the inhaler at the same time each day.
Rinse the mouth with water after inhalation to reduce the risk of oral fungal infection.
Do not exceed the prescribed dose.
Do not stop treatment without consulting your physician.
Possible Side Effects
Some patients may experience:
Dry mouth
Headache
Sore throat
Hoarseness
Oral candidiasis (thrush)
Cough
Increased heart rate
Muscle cramps
Seek medical attention if severe allergic reactions or worsening breathing symptoms occur.
Storage
Store below the temperature recommended on the product label.
Protect from excessive heat and moisture.
Keep out of reach of children.
Countries with High Clinical Use
This triple therapy is widely prescribed by respiratory physicians in countries with a high burden of COPD and asthma, including:
United States
United Kingdom
Canada
Australia
Germany
France
Italy
Spain
Saudi Arabia
United Arab Emirates
South Africa
Singapore
Malaysia
Philippines
New Zealand
These markets have established respiratory treatment guidelines where triple inhaled therapy is commonly used for eligible patients under physician supervision.
Why Choose Cordium Pharmaceuticals?
Cordium Pharmaceuticals is committed to delivering reliable pharmaceutical export solutions worldwide.
Our strengths include:
Quality-assured pharmaceutical products
Export support for international buyers
Competitive pricing
Regulatory documentation assistance
Bulk supply capability
Timely worldwide shipments
Professional customer support
Customized private-label and contract manufacturing options (subject to regulatory requirements)
Global Export Availability
Cordium Pharmaceuticals supports international pharmaceutical supply to licensed importers and distributors in accordance with the regulations of the importing country. Product availability depends on local registration requirements, import regulations, and applicable laws.
For export inquiries, regulatory documentation, pricing, or bulk orders:
Cordium Pharmaceuticals
š± WhatsApp: +91-9405117673
š§ Email: info@cordiumpharma.com
Respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and severe asthma continue to affect millions of people worldwide. The combination of Vilanterol, Glycopyrronium, and Fluticasone provides comprehensive symptom control by combining three proven medicines in one inhaler. This triple therapy is widely prescribed by respiratory specialists for patients requiring long-term maintenance treatment.
Cordium Pharmaceuticals is a trusted pharmaceutical exporter from India, supplying high-quality respiratory medicines to international distributors, hospitals, pharmacies, government procurement agencies, and healthcare organizations.
Composition
Each inhaler contains:
Vilanterol (Long-Acting Beta2 Agonist ā LABA)
Glycopyrronium (Long-Acting Muscarinic Antagonist ā LAMA)
Fluticasone (Inhaled Corticosteroid ā ICS)
This triple combination helps improve lung function, reduces airway inflammation, and keeps the airways open for easier breathing.
Medical Benefits
Provides long-lasting bronchodilation.
Reduces airway inflammation.
Improves breathing capacity.
Helps decrease COPD exacerbations.
Reduces hospitalization risk.
Improves exercise tolerance.
Enhances quality of life.
Convenient once-daily maintenance therapy.
Supports long-term respiratory disease management.
Indications
This medicine is commonly prescribed for:
Chronic Obstructive Pulmonary Disease (COPD)
Severe persistent asthma (when appropriate and prescribed by a physician)
Patients with frequent respiratory exacerbations requiring triple inhaled therapy
Note: This inhaler is a maintenance treatment and is not intended for the immediate relief of sudden breathing attacks.
Dosage and Administration
Use only as directed by a qualified healthcare professional.
The commonly prescribed regimen is one inhalation once daily, depending on the specific strength and product approved in the destination country.
Use the inhaler at the same time each day.
Rinse the mouth with water after inhalation to reduce the risk of oral fungal infection.
Do not exceed the prescribed dose.
Do not stop treatment without consulting your physician.
Possible Side Effects
Some patients may experience:
Dry mouth
Headache
Sore throat
Hoarseness
Oral candidiasis (thrush)
Cough
Increased heart rate
Muscle cramps
Seek medical attention if severe allergic reactions or worsening breathing symptoms occur.
Storage
Store below the temperature recommended on the product label.
Protect from excessive heat and moisture.
Keep out of reach of children.
Countries with High Clinical Use
This triple therapy is widely prescribed by respiratory physicians in countries with a high burden of COPD and asthma, including:
United States
United Kingdom
Canada
Australia
Germany
France
Italy
Spain
Saudi Arabia
United Arab Emirates
South Africa
Singapore
Malaysia
Philippines
New Zealand
These markets have established respiratory treatment guidelines where triple inhaled therapy is commonly used for eligible patients under physician supervision.
Why Choose Cordium Pharmaceuticals?
Cordium Pharmaceuticals is committed to delivering reliable pharmaceutical export solutions worldwide.
Our strengths include:
Quality-assured pharmaceutical products
Export support for international buyers
Competitive pricing
Regulatory documentation assistance
Bulk supply capability
Timely worldwide shipments
Professional customer support
Customized private-label and contract manufacturing options (subject to regulatory requirements)
Global Export Availability
Cordium Pharmaceuticals supports international pharmaceutical supply to licensed importers and distributors in accordance with the regulations of the importing country. Product availability depends on local registration requirements, import regulations, and applicable laws.
For export inquiries, regulatory documentation, pricing, or bulk orders:
Cordium Pharmaceuticals
š± WhatsApp: +91-9405117673
š§ Email: info@cordiumpharma.com
Keywords
